Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer.
Authors
Joseph, NuradhDovedi, Simon J
Thompson, C
Lyons, Jeanette
Kennedy, J
Elliott, Tony
West, Catharine M L
Choudhury, Ananya
Affiliation
Department of Clinical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, ManchesterIssue Date
2015-11-16
Metadata
Show full item recordAbstract
Pre-treatment lymphocytopaenia may result from cytokines secreted by the tumour microenvironment in association with aggressive tumour biology. We sought to establish the prognostic significance of lymphocytopaenia in muscle invasive and advanced bladder cancer.Citation
Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. 2015: Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdv546PubMed ID
26578732Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdv546